• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Patient Enrollment Commences for Tuberculosis Clinical Development Program Using Xenomics' Transrenal DNA Diagnostic Technology

Posted on: Wednesday, 14 June 2006, 03:00 CDT

NEW YORK, June 14 /PRNewswire-FirstCall/ -- Xenomics, Inc. (OTC Bulletin Board: XNOM; FWB: XE7), the source of next-generation medical DNA diagnostic technologies, announced today initiation of patient enrollment in Europe for its clinical development program of a tuberculosis test using its proprietary Transrenal DNA (Tr-DNA)-based technology.

SpaXen Italia, S.R.L., a collaborative venture between Xenomics and Italy's National Institute for Infectious Diseases "Lazzaro Spallanzani" (INMI), will lead an international consortium focusing on the development of a diagnostic test for tuberculosis utilizing Xenomics' Tr-DNA technology.

"Enrolling patients is an important milestone for this clinical development program," said Dr. Enrico Girardi, a leading tuberculosis researcher with INMI. "We are excited about using Xenomics' urine Tr-DNA-based diagnostic technology which will foster fundamental improvements in safety, accuracy and functionality of diagnostic testing for tuberculosis."

Currently, the definitive diagnostic test for tuberculosis is a culture which takes up to three months to complete and is not always reliable. Therefore, individuals with tuberculosis often may be unaware of their condition during that period during which they may be highly infectious. This is a serious problem in many parts of the developing world and a growing problem in the USA.

"Xenomics' technology is based upon the fact that cellular DNA from throughout the body cross the kidney barrier and accumulates in the urine," said Dr. L. David Tomei, CEO and Co-Founder of Xenomics. "Through the analysis of easily obtained urine samples, these Tr-DNA fragments provide immediate and vital information about a wide range of conditions inside the body, including serious infectious diseases."

About SpaXen Italia, S.R.L.:

SpaXen Italia is a collaborative venture of Xenomics and the National Institute for Infectious Diseases "Lazzaro Spallanzani." Its mission is to conduct research on detection of infectious diseases.

About the National Institute for Infectious Diseases:

Established in 1936, the National Institute for Infectious Diseases (Istituto Nazionale per la Malattie Infettive "Lazarus Spallanzani") is devoted to the prevention, diagnosis and care of infectious diseases. Centrally located in Rome, it is among the leading health care and research institutions in Europe and throughout the world.

About the Consortium:

The Consortium consisting of world-renown clinical researchers with Italy's National Institute for Infectious Diseases, the University College of London, the University of Zambia School of Medicine, the University of Munich, the Mbeya Medical Research Programme, and the Foundation for Innovative New Diagnostics.

About Xenomics, Inc.

Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA (Tr-DNA). Xenomics' patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. Scientists from Xenomics were the first to report that fragments of DNA from normal cell death cross the kidney barrier and can be detected in urine. The Company believes that its technology will open significant new markets in the molecular diagnostics field. Xenomics has three issued U.S. patents covering different applications of the technology for molecular diagnostics and genetic testing and a corresponding allowed European patent for the Company's prenatal testing applications. The Company has organized a joint venture to conduct research on infectious disease detection with the National Institute for Infectious Diseases (Istituto Nazionale per la Malattie Infettive "Lazarus Spallanzani") in Rome, in the form of a research and development company called SpaXen Italia, S.R.L. For additional information, please visit http://www.xenomics.com/. Xenomics' stock trades under the symbol XNOM.OB and is also listed on the Frankfurt Stock Exchange under the symbol XE7.

Forward-Looking Statements

Certain statements made in this press release are forward looking. Such statements are indicated by words such as "expect,""might,""should,""anticipate" and similar words indicating uncertainty in facts and figures. Although Xenomics believes that the expectations reflected in such forward- looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in Xenomics' Form 10-KSB as filed with the Securities and Exchange Commission on May 16, 2006, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that Xenomics will not obtain approval to market its products, the risk that Xenomics' technology will not gain market acceptance, the risks associated with dependence upon key personnel, and the need for additional financing.

Contact: Xenomics, Inc. L. David Tomei 212-297-0808 ldtomei@xenomics.com

Xenomics, Inc.

CONTACT: L. David Tomei of Xenomics, Inc., +1-212-297-0808, orldtomei@xenomics.com

Web site: http://www.xenomics.com/

Source: PRNewswire-FirstCall

More News in this Category